The safety of afatinib for the treatment of non-small cell lung cancer.
about
CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation.Extending the curve: survival of EGFR-mutated lung cancer patients in the 21st century.
P2860
The safety of afatinib for the treatment of non-small cell lung cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The safety of afatinib for the treatment of non-small cell lung cancer.
@en
type
label
The safety of afatinib for the treatment of non-small cell lung cancer.
@en
prefLabel
The safety of afatinib for the treatment of non-small cell lung cancer.
@en
P2093
P2860
P1476
The safety of afatinib for the treatment of non-small cell lung cancer
@en
P2093
Andres F Cardona
Feliciano Barron
Martha de la Torre-Vallejo
Rosa Luz Luna-Palencia
P2860
P304
P356
10.1080/14740338.2016.1236910
P407
P577
2016-09-28T00:00:00Z